Estrella Immunopharma Net Income
| ESLA Stock | 1.24 0.01 0.81% |
As of the 13th of February 2026, Estrella Immunopharma shows the Mean Deviation of 6.5, standard deviation of 8.34, and Variance of 69.59. Estrella Immunopharma technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Estrella Immunopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Estrella Immunopharma's valuation are provided below:We have found eighty-seven available fundamental signals for Estrella Immunopharma, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Estrella Immunopharma prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -6.6 M | -6.9 M | |
| Net Loss | -10 M | -9.5 M | |
| Net Loss | -8 M | -7.6 M | |
| Net Loss | (0.28) | (0.29) | |
| Net Income Per E B T | 1.15 | 1.13 |
Estrella | Net Income | Build AI portfolio with Estrella Stock |
Analyzing Estrella Immunopharma's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Estrella Immunopharma's current valuation and future prospects.
Latest Estrella Immunopharma's Net Income Growth Pattern
Below is the plot of the Net Income of Estrella Immunopharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Estrella Immunopharma financial statement analysis. It represents the amount of money remaining after all of Estrella Immunopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Estrella Immunopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Estrella Immunopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.85 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Estrella Net Income Regression Statistics
| Arithmetic Mean | (2,496,413) | |
| Coefficient Of Variation | (125.15) | |
| Mean Deviation | 2,553,093 | |
| Median | (733,693) | |
| Standard Deviation | 3,124,328 | |
| Sample Variance | 9.8T | |
| Range | 8.1M | |
| R-Value | (0.76) | |
| Mean Square Error | 4.5T | |
| R-Squared | 0.57 | |
| Significance | 0.0005 | |
| Slope | (467,478) | |
| Total Sum of Squares | 156.2T |
Estrella Net Income History
Other Fundumenentals of Estrella Immunopharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Estrella Immunopharma Net Income component correlations
Estrella Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Estrella Immunopharma is extremely important. It helps to project a fair market value of Estrella Stock properly, considering its historical fundamentals such as Net Income. Since Estrella Immunopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Estrella Immunopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Estrella Immunopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. Projected growth potential of Estrella fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Estrella Immunopharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Estrella Immunopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Estrella Immunopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Estrella Immunopharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Estrella Immunopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Estrella Immunopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Estrella Immunopharma.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Estrella Immunopharma on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Estrella Immunopharma or generate 0.0% return on investment in Estrella Immunopharma over 90 days. Estrella Immunopharma is related to or competes with EXoZymes, Greenwich Lifesciences, Atossa Genetics, Surrozen, Anebulo Pharmaceuticals, Tevogen Bio, and Oncolytics Biotech. Estrella Immunopharma is entity of United States More
Estrella Immunopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Estrella Immunopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Estrella Immunopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 34.57 | |||
| Value At Risk | (14.69) | |||
| Potential Upside | 12.21 |
Estrella Immunopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Estrella Immunopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Estrella Immunopharma's standard deviation. In reality, there are many statistical measures that can use Estrella Immunopharma historical prices to predict the future Estrella Immunopharma's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.97) | |||
| Total Risk Alpha | (1.70) | |||
| Treynor Ratio | 7.08 |
Estrella Immunopharma February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 7.09 | |||
| Mean Deviation | 6.5 | |||
| Coefficient Of Variation | (864.13) | |||
| Standard Deviation | 8.34 | |||
| Variance | 69.59 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.97) | |||
| Total Risk Alpha | (1.70) | |||
| Treynor Ratio | 7.08 | |||
| Maximum Drawdown | 34.57 | |||
| Value At Risk | (14.69) | |||
| Potential Upside | 12.21 | |||
| Skewness | 0.4551 | |||
| Kurtosis | 1.04 |
Estrella Immunopharma Backtested Returns
Estrella Immunopharma secures Sharpe Ratio (or Efficiency) of -0.0464, which denotes the company had a -0.0464 % return per unit of risk over the last 3 months. Estrella Immunopharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Estrella Immunopharma's Standard Deviation of 8.34, variance of 69.59, and Mean Deviation of 6.5 to check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.14, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Estrella Immunopharma are expected to decrease at a much lower rate. During the bear market, Estrella Immunopharma is likely to outperform the market. At this point, Estrella Immunopharma has a negative expected return of -0.37%. Please make sure to confirm Estrella Immunopharma's day median price, price action indicator, as well as the relationship between the accumulation distribution and potential upside , to decide if Estrella Immunopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.41 |
Modest reverse predictability
Estrella Immunopharma has modest reverse predictability. Overlapping area represents the amount of predictability between Estrella Immunopharma time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Estrella Immunopharma price movement. The serial correlation of -0.41 indicates that just about 41.0% of current Estrella Immunopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.41 | |
| Spearman Rank Test | 0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Estrella Operating Income
Operating Income |
|
Based on the recorded statements, Estrella Immunopharma reported net income of (8.85 Million). This is 102.59% lower than that of the Biotechnology sector and 112.63% lower than that of the Health Care industry. The net income for all United States stocks is 101.55% higher than that of the company.
Estrella Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Estrella Immunopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Estrella Immunopharma could also be used in its relative valuation, which is a method of valuing Estrella Immunopharma by comparing valuation metrics of similar companies.Estrella Immunopharma is currently under evaluation in net income category among its peers.
Estrella Fundamentals
| Return On Equity | -2.68 | ||||
| Return On Asset | -1.01 | ||||
| Current Valuation | 53.02 M | ||||
| Shares Outstanding | 37.07 M | ||||
| Shares Owned By Insiders | 70.36 % | ||||
| Shares Owned By Institutions | 2.05 % | ||||
| Number Of Shares Shorted | 943.48 K | ||||
| Price To Book | 241.30 X | ||||
| EBITDA | (8.85 M) | ||||
| Net Income | (8.85 M) | ||||
| Total Debt | 3 M | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (7.64 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (0.24) X | ||||
| Target Price | 16.0 | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 81.54 M | ||||
| Total Asset | 3.14 M | ||||
| Retained Earnings | (23.93 M) | ||||
| Working Capital | 4.27 M | ||||
| Net Asset | 3.14 M |
About Estrella Immunopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Estrella Immunopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Estrella Immunopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Estrella Immunopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Estrella Immunopharma is a strong investment it is important to analyze Estrella Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Estrella Immunopharma's future performance. For an informed investment choice regarding Estrella Stock, refer to the following important reports:Check out For information on how to trade Estrella Stock refer to our How to Trade Estrella Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. Projected growth potential of Estrella fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Estrella Immunopharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Estrella Immunopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Estrella Immunopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Estrella Immunopharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.